Literature DB >> 18388494

Meningococcal B vaccine development and evaluation of efficacy.

Loek van Alphen1, Germie van den Dobbelsteen.   

Abstract

In this commentary we stress that serum bactericidal activity is now internationally accepted as correlate of protection for evaluating new vaccines for epidemic and endemic meningococcal B control, and that the standardization of the assay and the choice of representative strains for each of the vaccine candidates are critical.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18388494     DOI: 10.4161/hv.4.2.4871

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  7 in total

1.  From genes to vaccine: A breakthrough in the prevention of meningococcal group B disease.

Authors:  Maria Major; Steven Moss; Ronald Gold
Journal:  Paediatr Child Health       Date:  2011-10       Impact factor: 2.253

Review 2.  Review of meningococcal group B vaccines.

Authors:  Dan M Granoff
Journal:  Clin Infect Dis       Date:  2010-03-01       Impact factor: 9.079

3.  Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37.

Authors:  K L Seib; D Serruto; F Oriente; I Delany; J Adu-Bobie; D Veggi; B Aricò; R Rappuoli; M Pizza
Journal:  Infect Immun       Date:  2008-10-13       Impact factor: 3.441

Review 4.  Utilizing complement evasion strategies to design complement-based antibacterial immunotherapeutics: Lessons from the pathogenic Neisseriae.

Authors:  Sanjay Ram; Jutamas Shaughnessy; Rosane B DeOliveira; Lisa A Lewis; Sunita Gulati; Peter A Rice
Journal:  Immunobiology       Date:  2016-06-01       Impact factor: 3.144

Review 5.  Vaccine development against Neisseria meningitidis.

Authors:  Ulrich Vogel; Heike Claus
Journal:  Microb Biotechnol       Date:  2011-01       Impact factor: 5.813

6.  Meningococcal Group B Vaccine For The Prevention Of Invasive Meningococcal Disease Caused By Neisseria meningitidis Serogroup B.

Authors:  Irene Rivero-Calle; Peter Francis Raguindin; Jose Gómez-Rial; Carmen Rodriguez-Tenreiro; Federico Martinón-Torres
Journal:  Infect Drug Resist       Date:  2019-10-09       Impact factor: 4.003

7.  Routine vaccination against MenB: considerations for implementation.

Authors:  Patricia Kaaijk; Arie van der Ende; Willem Luytjes
Journal:  Hum Vaccin Immunother       Date:  2013-10-18       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.